Earnings call transcript: Doximity’s Q4 2026 EPS Misses, Stock Drops 11.57%

Doximity posted mixed Q4 fiscal 2026 results: revenue of $145.4 million beat estimates by 0.9%, but EPS of $0.26 missed consensus by 7.1%, and the stock fell 11.6% in aftermarket trading to $26.36. Free cash flow remained strong at $107 million, but gross margin slipped to 89% from 91% due to rising AI compute costs. Management guided fiscal 2027 revenue to $664 million-$676 million and said AI investment will continue to pressure margins near term.

Analysis

The key second-order effect is that DOCS is trading like a “good business, bad setup” name: core engagement is compounding, but the market is punishing the bridge period where AI usage expands faster than monetization. That creates an unusual asymmetry: near-term margins can compress even while the product becomes more strategically embedded, which is why the selloff is more about timing than terminal value. In our view, the biggest competitive moat is not the model itself but the hospital approval layer; once AI workflows are embedded inside compliant systems, switching costs rise materially and competitors are pushed into a much narrower lane.

The market is underestimating how the AI launch changes bargaining power in the legacy pharma ad business. Even if AI Search revenue is small in the first half, it gives sales a new premium SKU that can re-open budget conversations with brands that have gone defensive, and it may pull spend back from lower-quality channels into DOCS over the next two budget cycles. That said, there is a real execution risk that the company overbuilds compute ahead of monetization, leaving gross margin pressure visible for several quarters and capping multiple expansion until investors see actual AI revenue inflect.

The contrarian view is that the move down may already discount a lot of the bad news, while missing the option value of a new budget category. The stock is now pricing DOCS more like a cyclical ad platform than a sticky workflow network, which seems too punitive if AI adoption keeps compounding into next fiscal year. The cleaner tell over the next 60-120 days will be whether health-system approvals continue to rise faster than AI usage; if that gap narrows, the market should start rewarding the company for monetization leverage rather than penalizing it for investment intensity.

Key Decisions for Investors

• Go long DOCS on further post-earnings weakness only if the stock stabilizes for 2-3 sessions; target a 3-6 month mean reversion trade with 20-30% upside if management can show AI monetization traction, but keep a hard stop below the earnings-gap low.
• For event-driven traders, buy DOCS Sep/Dec call spreads rather than outright calls: the setup is a delayed-catalyst story, and spread structure limits theta bleed while preserving upside if AI Search converts before year-end.
• Pair trade: long DOCS / short a lower-quality digital health or ad-tech peer with weaker balance sheets and no embedded workflow moat over the next 1-2 quarters; DOCS should outperform once investors focus on engagement durability versus temporary margin pressure.
• If holding DOCS common, hedge with short-dated puts into the next print; the stock remains vulnerable to any evidence that AI compute costs outrun revenue again, and the market will likely punish another margin miss before rewarding the long-term story.
• Avoid chasing the selloff in pure short form unless gross margin deterioration accelerates for two consecutive quarters; the risk/reward on the short side is deteriorating because the market is starting to underwrite DOCS as a strategic platform, not a single-quarter EPS miss.